Neurotech funding 2025 full-year reaches $4.8B — BCI sector alone raises $3.2B, largest annual total in history
Summary
Full-year 2025 neurotechnology funding reached approximately $4.8 billion across around 140 disclosed rounds, representing the largest annual total in the sector's history — more than double the 2024 total of approximately $2.3B. BCI companies alone raised approximately $3.2B led by Neuralink's $650M Series E and Synchron's $200M Series D. Neuromodulation was second with $385M across 12 deals. The surge reflects growing mainstream institutional investor confidence following Neuralink's clinical milestones and Medtronic's adaptive DBS FDA approval.
Why it matters
A $4.8B annual neurotech funding total — exceeding the cumulative total raised by the entire sector in the previous five years — marks the definitive crossover of neurotech from deep tech niche to mainstream biotech/medtech asset class. This will attract an entirely new set of institutional investors, strategic pharma partners, and government policy attention.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial